Cakes and drinks sweetener neotame can damage gut wall, scientists find
Industry ’s sugar substitute E961 can have ‘toxic effect on health’, says study finding sweetener capable of damaging intestinal bacteriaA sweetener used in cakes, soft drinks and chewing gum can seriously damage people ’s health by weakening the gut, anew study has found.Consumption of even a small amount of the sweetener neotame can lead to someone starting to suffer irritable bowel syndrome, insulin resistance, and even sepsis, a condition that kills about 40,000 in Britain a year.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - April 24, 2024 Category: Science Authors: Denis Campbell Health policy editor Tags: Food safety Soft drinks Nutrition Irritable bowel syndrome & drink industry Health policy Diabetes Science Business Source Type: news
South Africa: Department of Health Fails to Buy Life-Saving Device for Diabetes Patients
[GroundUp] Using vials and syringes instead of pens can lead to insulin dosing errors which can be fatal (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - April 24, 2024 Category: African Health Tags: Health and Medicine South Africa Southern Africa Source Type: news
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It ’s not that clear-cut
President Joe Biden frequently cites insulin prices as he promotes a $35 price cap for Americans with diabetes who are on Medicare.#medicare (Source: Reuters: Health)
Source: Reuters: Health - April 21, 2024 Category: Consumer Health News Source Type: news
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
President Joe Biden frequently cites insulin prices as he promotes a $35 price cap for Americans with diabetes who are on Medicare (Source: ABC News: Health)
Source: ABC News: Health - April 21, 2024 Category: Consumer Health News Tags: Health Source Type: news
Inside Novo Nordisk, the Company Behind Ozempic and Wegovy
Novo Nordisk ’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions. (Source: NYT Health)
Source: NYT Health - April 20, 2024 Category: Consumer Health News Authors: Eshe Nelson and Charlotte de la Fuente Tags: Drugs (Pharmaceuticals) Semaglutide (Drug) Weight Ozempic (Drug) Prices (Fares, Fees and Rates) Obesity Workplace Environment Insulin Novo Nordisk A/S Sanders, Bernard Denmark Jorgensen, Lars Fruergaard Wegovy (Drug) Source Type: news
Temporary Gut Liner Lowers Weight, A1c Temporary Gut Liner Lowers Weight, A1c
Data on the investigative, temporary gut liner, EndoBarrier, showed improvement in weight, A1c, fatty liver, and need for insulin, and the effect persisted for up to 2 years after its removal.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 19, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Placenta Plays Role in Gestational Diabetes, Study Suggests
WEDNESDAY, April 17, 2024 -- The placenta could be one reason why some women develop gestational diabetes during pregnancy, a new study finds.A deficit in the way the placenta expresses the gene for a hormone called insulin-like growth factor 1... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 17, 2024 Category: General Medicine Source Type: news
Increased Retinopathy Risk Seen With GLP-1RAs for Diabetes Increased Retinopathy Risk Seen With GLP-1RAs for Diabetes
But diabetes-related eye complication risks were reduced with SGLT2 inhibitors and insulin.Medscape News UK (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - April 16, 2024 Category: Primary Care Tags: Internal Medicine Clinical Summary Source Type: news
Ozempic Hurts the Fight Against Eating Disorders
It’s impossible to escape the soaring popularity of Ozempic and similar drugs these days—daily headlines, celebrity “success” stories, and apparent ease in procuring prescriptions (even Costco sells them now) abound. But the cumulative effect of all of this has many experts in the eating disorder field worried about how this might affect their patients. This makes sense—even for those without eating disorders, these drugs can feel both triggering and enticing. After all, research tells us about 90% of women are dissatisfied with their bodies. This sounds like a quick fix.
[time-brightcove not-...
Source: TIME: Health - April 16, 2024 Category: Consumer Health News Authors: Cole Kazdin Tags: Uncategorized freelance Source Type: news
Sugar Substitutes Satisfy Appetite, Blunt Insulin Response Sugar Substitutes Satisfy Appetite, Blunt Insulin Response
Replacing sugar with sweeteners didn ' t increase appetite and lowered blood glucose levels in adults with overweight and obesity, showed a randomized trial.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 16, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology Clinical Summary Source Type: news
How to reverse insulin resistance
In a Q&A, Yale ’s Gerald Shulman discusses the basics of insulin resistance, how the condition impacts our health, and the steps we can take to reverse it. (Source: Yale Science and Health News)
Source: Yale Science and Health News - April 11, 2024 Category: Universities & Medical Training Source Type: news
This outdated diabetes drug still has something to offer
Thiazolidinediones (TZDs) are a class of drug that can be used to treat type 2 diabetes by reversing insulin resistance, one of the main hallmarks of the disease. While TZDs were extremely popular in the 1990’s and early 2000’s, they have fallen out of use among physicians in recent decades because they were discovered to cause unwanted side effects, including weight gain and excess fluid accumulation in body tissues. (Source: World Pharma News)
Source: World Pharma News - April 11, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Invitation: Roche Diagnostics Investor Day 2024
The Roche Investor Relations team would like to invite you to the Roche Diagnostics Investor Day that will take place in London on Wednesday, 22 May 2024, starting at 12:00 BST local time and will finish at 15:30 BST with a reception.The Roche Diagnostics Investor Day will address the following topics:Mass spectrometryContinuous glucose monitoringNext generation sequencingPoint of careUpcoming molecular diagnostics launchesNeurology biomarkers in development Presenters include:Matt Sause, CEO Roche DiagnosticsAlan Hippe, Chief Financial and IT OfficerPalani Kumaresan, Global Head of Roche Diagnostics Solutions (RDS)B...
Source: Roche Investor Update - April 10, 2024 Category: Pharmaceuticals Source Type: news
Let more NHS staff work flexibly to help solve staffing crisis
NHS managers should do more to allow staff to work in flexible ways, including having more control over shift patterns or doing compressed hours*, says UNISON today (Wednesday).
Data from a new UNISON survey** shows a significant proportion of healthcare workers are not being given the alternative work patterns they’ve asked for.
The survey found two-thirds (65%) of women employed in healthcare across the UK who’ve asked for different work arrangements had their requests agreed in full.
But more than one in five (22%) were unable to obtain flexible working. A further one in eight (13%) had their requests ini...
Source: UNISON meat hygiene - April 10, 2024 Category: Food Science Authors: Anthony Barnes Tags: News Press release 2024 National Health Conference flexible working NHS staff Source Type: news
America ’ s Growing Birthweight Crisis
Americans are increasingly at risk of having lower incomes, poorer health, and a worse shot at opportunity even before they are born. More babies are now born with low birthweights than in the last 30 years. This has caused growing inequalities that can persist if not properly addressed. In certain parts of the country, that risk may be ten-times greater.
Underweight newborns are at an increased risk of long term health challenges, lower IQ scores, and developmental delays. New data shows that the frequency of this problem is rising with more than 300,000 newborns now experiencing low birthweight. This public hea...
Source: TIME: Health - April 9, 2024 Category: Consumer Health News Authors: Jeremy Ney Tags: Uncategorized freelance Source Type: news
